To provide methods for treating hyperkinetic diseases and disorders, such as tardive dyskinesia.SOLUTION: In a certain embodiment, the potent VMAT2 inhibitor (+)α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol ((+)α-HTBZ) is used in the methods described herein for treating a subject in need thereof. In one aspect, the methods comprise administering: (a) tetrabenazine (TBZ); (b) (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester; (c) deuterated TBZ; or the like.SELECTED DRAWING: None
VMAT2 INHIBITOR FOR TREATMENT OF HYPERKINETIC MOVEMENT DISORDERS